HighTide Therapeutics Inc (2511.HK)
HKD 1.11
(14.43%)
HKD 1.11
(14.43%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | - | - | - |
| Cost of Revenue | 2.02 Million | 1.48 Million | 1.91 Million |
| Gross Profit | -2.02 Million | -1.48 Million | -1.91 Million |
| Operating Expenses | 438.33 Million | 261.42 Million | 157.26 Million |
| Selling, General and Administrative Expenses | 136.67 Million | 49.02 Million | 56.01 Million |
| Research and Development Expenses | 344.28 Million | 212.4 Million | 101.25 Million |
| Other Expenses | -524.77 Million | 15.91 Million | -93.61 Million |
| Cost and Expenses | 438.33 Million | 262.9 Million | 159.17 Million |
| Operating Income | -440.35 Million | -262.9 Million | -159.17 Million |
| Interest Expense | 400 Thousand | 426 Thousand | 4.52 Million |
| Income Tax Expense | 83.97 Thousand | 37.21 Thousand | 115.7 Thousand |
| Earnings before Tax | -939.23 Million | -221.18 Million | -266.41 Million |
| Net Income | -1.03 Billion | -221.22 Million | -266.52 Million |
| Earnings Per Share Basic | -2.02 | -0.43 | -0.52 |
| Earnings Per Share Diluted | -2.02 | -0.43 | -0.52 |
| Weighted Average Shares Outstanding | 514.77 Million | 514.77 Million | 514.77 Million |
| Weighted Average Shares Outstanding (Diluted) | 514.77 Million | 514.77 Million | 514.77 Million |
| Gross Margin | - | - | - |
| EBIT Margin | - | - | - |
| Profit Margin | - | - | - |
| EBITDA | -959.42 Million | -261.42 Million | -157.26 Million |
| Earnings Before Tax Margin | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 3.12 Million | - | 2.02 Million | 1.09 Million | - | 923.98 Thousand |
| Gross Profit | -3.12 Million | - | -2.02 Million | -1.09 Million | - | -923.98 Thousand |
| Operating Expenses | 133.25 Thousand | 134.4 Thousand | 454.37 Million | 276.81 Million | 148.08 Thousand | 175.26 Million |
| Selling, General and Administrative Expenses | 24.74 Thousand | 24.95 Thousand | - | 69.95 Million | 45.39 Thousand | 39.44 Million |
| Research and Development Expenses | 108.51 Thousand | 109.44 Thousand | - | 206.86 Million | 102.68 Thousand | 135.81 Million |
| Other Expenses | - | - | -524.77 Million | - | - | - |
| Cost and Expenses | 133.25 Thousand | 134.4 Thousand | 456.39 Million | 277.9 Million | 148.08 Thousand | 176.18 Million |
| Operating Income | -133.25 Thousand | -134.4 Thousand | -456.39 Million | -277.9 Million | -148.08 Thousand | -176.18 Million |
| Interest Expense | 521.22 Thousand | - | 400 Thousand | 214.98 Thousand | - | 227.32 Thousand |
| Income Tax Expense | 289.05 | 291.54 | 83.97 Thousand | 54.01 Thousand | 26.81 | 29.4 Thousand |
| Earnings before Tax | -113.04 Thousand | -114.01 Thousand | -1.03 Billion | -420.8 Million | -208.88 Thousand | -621.7 Million |
| Net Income | -113.33 Thousand | -114.3 Thousand | -1.03 Billion | -420.85 Million | -208.91 Thousand | -621.73 Million |
| Earnings Per Share Basic | -0.00 | -0.00 | - | -0.82 | -0.00 | -1.21 |
| Earnings Per Share Diluted | -0.00 | -0.00 | - | -0.82 | -0.00 | -1.21 |
| Weighted Average Shares Outstanding | 452.07 Million | 452.07 Million | 514.77 Million | 514.77 Million | 476.9 Million | 514.77 Million |
| Weighted Average Shares Outstanding (Diluted) | 452.07 Million | 452.07 Million | 514.77 Million | 514.77 Million | 476.9 Million | 514.77 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -133.02 Thousand | -134.16 Thousand | - | -276.81 Million | -147.89 Thousand | -175.26 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
MLEDR
300706
SEGXF
FSTJ
600006
EXO